Features
Preparing Retina Fellows for the Future
Part 2 of a 3-part series on medical and surgical retina.
By Susan L. Worley, contributing writer
Articles
Ocular Inflammation After Intravitreal Injections
A review of data on incidence and implications.
A Deep Dive Into OCTA
Experts discuss wet AMD, image interpretation, vascular imaging, new advances, and reimbursement.
Positive Phase 2 Bispecific Antibody Data Presented
RG7716 meets primary endpoint in BOULEVARD Phase 2 DME trial.
Role of OCT Angiography in Neovascular AMD
Benefits in diagnosis and clinic workflow.
Practical Pearls for OCTA Image Interpretation
Become familiar with common challenges to overcome pitfalls.
Retinal Vascular Imaging With OCTA
High-resolution images of the retinal and choroidal vasculature.
Squalamine Eye Drop Fails in Wet AMD
No benefit seen when combined with Lucentis.
Upcoming Advances in Optical Coherence Tomography Angiography
Improvements could make OCTA a mainstay for retinal imaging.
OCT Angiography: An Economic and Ethical Dilemma for Ophthalmologists in the United States
Retina specialists have the responsibility of educating regulatory bodies.
Developments in Intraoperative OCT and Heads-Up Assisted Surgical Viewing
New technologies impact surgeon ergonomics as well as surgical techniques, management, and decision-making.
The Potential Role of Optical Coherence Tomography for Dementia Patients
Retinal imaging shows promise as a biomarker for dementia.
Lean Six Sigma Process Improvement in the Retina Clinic
Clinic efficiency can be improved using manufacturing analysis systems.
SUBSPECIALTY NEWS
By Jerry Helzner, contributing editor
RETINA CONVERSATIONS: A Conversation With Jeffrey S. Heier, MD
He found his niche in ophthalmic research.
CODING Q&A: Do You Know MPPR?
Payments can be reduced for certain diagnostic tests performed at the same time.
NEW PRODUCT APPLICATIONS: Improving Upon a Tried-and-True Device
Bausch + Lomb’s Vitesse system features a novel design for vitreous removal.
Visionaries of Vision
Carol and Jerry Shields set sights on ocular oncology cures and prevention, nothing less.